Fig 1.
Flow-chart of patient selection.
Table 1.
Patient characteristics.
Fig 2.
Distribution of TPMT activity.
TPMT activity in nmol/gHb/hr for patients with normal (gray) and heterozygous (black) TPMT genotype.
Fig 3.
Relapse free survival for TPMT genotypes and tertiles of TPMT activity.
Relapse free survival after start of cyclophosphamide induction therapy. Upper graph (3A): Variant = heterozygous TPMT variant carrier, Normal = normal genotype (wildtype TPMT). Lower graph (3B): T1 = lowest tertile, T2 = middle tertile, T3 = highest tertile of TPMT activity.
Table 2.
Adverse events in relation to TPMT genotype.
Table 3.
Adverse events in relation to TPMT activity.
Fig 4.
[leuko]*[aza] product over time for TPMT genotypes and tertiles of TPMT activity.
[leukocyte]*[azathioprine] product 3,6,9 and 12 months after switch to azathioprine. *P<0.05. Upper graph (4A): Variant = heterozygous TPMT variant carrier; Normal = normal genotype (wildtype TPMT). Lower graph (4B): T1 = lowest tertile, T2 = middle tertile, T3 = highest tertile of TPMT activity.